RecruitingOBSERVATIONAL

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

This study, called "Integrated Molecular and Clinical Profiling," is looking back at information from people diagnosed with Nodal Marginal Zone Lymphoma (NMZL) since 2000. It's an international study that collects existing medical records and stored tissue samples (like biopsies) to understand more about this type of lymphoma. The main goal is to find connections between changes in people's genes, their health information, and how their disease progresses. By doing this, researchers hope to develop better ways to classify NMZL and predict how it might affect individuals, which could lead to improved treatments and care for future patients.

At a glance

Status

Recruiting

Sponsor

International Extranodal Lymphoma Study Group (IELSG)

Enrolment target

300

Start

11 Apr 2024

Estimated completion

31 Dec 2026

Nodal Marginal Zone Lymphoma

What is this study about?

This study is called "Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma." That's a bit of a mouthful, but it simply means that researchers are trying to bring together (integrate) information about the tiny details of your cells (molecular) with your health story (clinical) to get a clearer picture of Nodal Marginal Zone Lymphoma (NMZL). By understanding the disease better, they hope to predict more accurately how it might behave in different people.

This isn't a study where you get a new treatment or medicine. Instead, it's what's called an "observational" study. The doctors and scientists involved are looking back at information that's already been collected from patients diagnosed in the past. This includes details from your medical notes and samples of tissue taken during a biopsy, which might have been stored in a special bank. They will examine these samples for tiny changes in your genes and other features to see if certain patterns are linked to how the lymphoma progresses, responds to treatment, or affects a person over time.

The main aim of doing all this is to find new ways to understand and group different types of NMZL. This deeper understanding could help doctors in the future make more informed decisions about the best course of action for each patient. By spotting patterns that lead to different outcomes, they might be able to tailor treatments more effectively for people newly diagnosed with NMZL.

Key takeaways

This study looks back at existing medical records and tissue samples.
It aims to better understand Nodal Marginal Zone Lymphoma (NMZL) at a genetic level.
No new treatments are given, and no extra appointments are needed.
The goal is to improve how NMZL is diagnosed and treated for future patients.
Your privacy is protected by using codes instead of names.

Who may be eligible?

To be included in this study, you would need to be an adult, 18 years old or over, who was diagnosed with Nodal Marginal Zone Lymphoma (NMZL) based on a lymph node biopsy. This diagnosis must have happened after January 1st, 2000.

Also, the researchers need to have a sample of your original lymph node tissue available, which was taken before you started any treatment for the lymphoma. They also need to be able to access your past and ongoing medical records related to your diagnosis and treatment.

You wouldn't be able to be part of the study if your Nodal Marginal Zone Lymphoma was actually a spread from another lymphoma that started somewhere else in your body, outside of the lymph nodes. Doctors would need to have carefully checked that this wasn't the case.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Were you diagnosed with Nodal Marginal Zone Lymphoma (NMZL) after January 1st, 2000?
Was your diagnosis based on a lymph node biopsy?
Do your doctors have a biopsy sample from before you started treatment?
Are your past medical records available for review?

Answer every question to see your result.

What does participation involve?

If you were to be involved in this study, you wouldn't need to do anything new. You wouldn't have any extra hospital visits, tests, or take any medication specifically for the study. The researchers are simply looking at information and samples that have already been collected as part of your past medical care. This means there's no direct participation needed from you once the study starts collecting information.

Potential risks and benefits

Because this study only uses existing medical information and banked tissue samples, there are no direct physical risks to you. Your medical information will be given a special code to protect your privacy. A potential benefit is that the knowledge gained from looking at your information, along with many other patients', could help doctors better understand Nodal Marginal Zone Lymphoma in the future and potentially lead to better care for others. You always have the right to request that your de-identified information no longer be used in the study, even though you aren't actively participating.

Locations (36)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

University of Miami
Verified postcode
Miami, United States· Recruiting
Weill Cornell Medical
Verified postcode
New York, United States· Recruiting
Hematology Center after Prof. Yeolyan
Verified postcode
Yerevan, Armenia· Recruiting
University Hospital Centre Zagreb
Verified postcode
Zagreb, Croatia· Not yet recruiting
AO SS Antonio e Biagio e C. Arrigo
Verified postcode
Alessandria, Italy· Recruiting
Istituto Tumori "Giovanni Paolo II" I.R.C.C.S.
Verified postcode
Bari, Italy· Recruiting
ASST Papa Giovanni XXIII
Verified postcode
Bergamo, Italy· Not yet recruiting
ASST degli Spedali Civili di Brescia
Verified postcode
Brescia, Italy· Not yet recruiting
AOU Policlinico Vittorio Emanuele, Presidio Ferrarotto
Verified postcode
Catania, Italy· Recruiting
Azienda Ospedaliero Universitaria di Ferrara
Verified postcode
Cona, Italy· Recruiting
Azienda Ospedaliera Universitaria Careggi
Verified postcode
Florence, Italy· Not yet recruiting
Azienda Ospedaliera Papardo
Verified postcode
Messina, Italy· Not yet recruiting

Common questions

What is Nodal Marginal Zone Lymphoma?

Nodal Marginal Zone Lymphoma (NMZL) is a slow-growing type of non-Hodgkin lymphoma, which is a cancer that starts in white blood cells called lymphocytes.

Will this study give me new medication?

No, this study is not testing new medications. It's looking at past medical information and tissue samples.

How will my personal information be kept private?

Your details will be assigned a unique numerical code, so your name and identifying information won't be directly linked to the data used for the study.

Do I need to go to extra appointments?

No, you don't need any additional appointments for this study. It uses information from your past medical records.

Will I get results from this study?

Individual results from this research will not be given to patients. The study aims to gather general knowledge to help future patients.

How to find out more

IELSG - Study Coordination Office

ielsg@ior.usi.ch +41586667321 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.